Author

Karolina Piasecka‐Stryczynska

Observed names: Karolina Piasecka Stryczynska, Karolina Piasecka-Stryczynska, Karolina Piasecka-Stryczyńska, Piasecka-Stryczynska, Karolina

Observed institutions: Poznan University of Medical Sciences, St. Michael's Hospital, University of Toronto, Tokuda Hospital, Acibadem City Clinic, Universitätsmedizin Göttingen, University of Göttingen

ORCID: 0000-0001-7000-3256

Observed ORCID: 0000-0001-7000-3256

OpenAlex ID: A5012486668

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

2019 · Xavier Montalban, Douglas L. Arnold, et al. · New England Journal of Medicine · 323

PDF

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine

2024 · Stewart J. Tepper, David W. Dodick, et al. · JAMA Neurology · 27

Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

2024 · Xavier Montalban, Karolina Piasecka-Stryczynska, et al. · Multiple Sclerosis Journal · 21

Concentration of evobrutinib, a BTK inhibitor, in cerebrospinal fluid during treatment of patients with relapsing multiple sclerosis in a phase 2 study

2021 · Karolina Piasecka-Stryczynska, Konrad Rejdak, et al. · Multiple Sclerosis and Related Disorders · 16

“Positive Regulation of RNA Metabolic Process” Ontology Group Highly Regulated in Porcine Oocytes Matured In Vitro: A Microarray Approach

2018 · Piotr Celichowski, Mariusz J. Nawrocki, et al. · BioMed Research International · 11

PDF

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study

2026 · Gavin Giovannoni, Gavin Giovannoni, et al. · The Lancet · 10

PDF

Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic

2023 · Adam Stępień, Aleksandra Pogoda-Wesołowska, et al. · Neurologia i Neurochirurgia Polska · 10

PDF

Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis

2022 · Karolina Piasecka-Stryczyńska, Łukasz Kaczyński, et al. · Neurologia i Neurochirurgia Polska · 9

PDF

Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis (4124)

2021 · Xavier Montalban, Douglas L. Arnold, et al. · Neurology · 5

Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study

2025 · Aleksandra Pogoda-Wesołowska, Adam Stępień, et al. · Frontiers in Neurology · 3

PDF

Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension (S16.008)

2023 · Xavier Montalban, Jerry S. Wolinsky, et al. · Neurology · 3

Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor in Relapsing Multiple Sclerosis Over 2.5 Years of The Open-Label Extension to a Phase II Trial (P5-4.001)

2022 · Xavier Montalban, Jerry S. Wolinsky, et al. · Neurology · 3

Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study

2025 · Stewart J. Tepper, David W. Dodick, et al. · European Journal of Neurology · 2

Update on Long-Term Efficacy and Safety of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Over 5 Years from an Ongoing Phase 2 Open-Label Extension

2023 · Xavier Montalban, Jerry S. Wolinsky, et al. · Multiple Sclerosis and Related Disorders · 2

056 Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study

2019 · Xavier Montalban, Douglas L Arnold, et al. · Journal of Neurology Neurosurgery & Psychiatry · 2

PDF

Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial

2026 · Richard J. Nowak, Kimiaki Utsugisawa, et al. · JAMA Neurology · 1

PDF

Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study (4131)

2021 · Xavier Montalban, Douglas L. Arnold, et al. · Neurology · 1

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study

2020 · Xavier Montalban, Douglas L Arnold, et al. · Multiple Sclerosis and Related Disorders · 1

PDF

Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study (S56.004)

2019 · Xavier Montalban, Douglas L. Arnold, et al. · Neurology · 1

Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials

2026 · Heinz Wiendl, Robert Bermel, et al. · The Lancet

Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial

2026 · J. Dawn Abbott, Jocelyne R. Benatar, et al. · Circulation

Taux de poussées chez les patients atteints de SEP rémittente traités par evobrutinib, un inhibiteur de la BTK : résultats d’extension de l’étude de phase II

2021 · Xavier Montalban, Douglas Arnold, et al. · Revue Neurologique

Works count: 24

Citation count: 451

H-index: 8

I10-index: 7